JP2013522652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522652A5 JP2013522652A5 JP2013501439A JP2013501439A JP2013522652A5 JP 2013522652 A5 JP2013522652 A5 JP 2013522652A5 JP 2013501439 A JP2013501439 A JP 2013501439A JP 2013501439 A JP2013501439 A JP 2013501439A JP 2013522652 A5 JP2013522652 A5 JP 2013522652A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- panel
- choline
- proline
- formate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims 16
- VEXDRERIMPLZLU-UHFFFAOYSA-N 3-hydroxy-2-methylbutanoic acid Chemical compound CC(O)C(C)C(O)=O VEXDRERIMPLZLU-UHFFFAOYSA-N 0.000 claims 12
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims 12
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 10
- 229960001231 choline Drugs 0.000 claims 10
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 10
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 8
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 8
- 235000013922 glutamic acid Nutrition 0.000 claims 8
- 239000004220 glutamic acid Substances 0.000 claims 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 8
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- 229960002255 azelaic acid Drugs 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 5
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- 235000021314 Palmitic acid Nutrition 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Substances 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 235000009697 arginine Nutrition 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 229940109239 creatinine Drugs 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 claims 4
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- HREXXXHMIGWWHU-UHFFFAOYSA-N 2-hydroxy-3-methylpent-2-enoic acid Chemical compound CCC(C)=C(O)C(O)=O HREXXXHMIGWWHU-UHFFFAOYSA-N 0.000 claims 2
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 claims 2
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 229940000635 beta-alanine Drugs 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 208000011581 secondary neoplasm Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 210000004243 sweat Anatomy 0.000 claims 2
- 230000004565 tumor cell growth Effects 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31667910P | 2010-03-23 | 2010-03-23 | |
| US61/316,679 | 2010-03-23 | ||
| PCT/US2011/029681 WO2011119772A1 (en) | 2010-03-23 | 2011-03-23 | Early detection of recurrent breast cancer using metabolite profiling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522652A JP2013522652A (ja) | 2013-06-13 |
| JP2013522652A5 true JP2013522652A5 (enExample) | 2014-05-08 |
Family
ID=44673604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501439A Pending JP2013522652A (ja) | 2010-03-23 | 2011-03-23 | 代謝物プロファイリングを用いた再発乳癌の早期検出 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130023056A1 (enExample) |
| EP (1) | EP2550533A4 (enExample) |
| JP (1) | JP2013522652A (enExample) |
| AU (1) | AU2011232434B2 (enExample) |
| CA (1) | CA2793735A1 (enExample) |
| MX (1) | MX2012010852A (enExample) |
| WO (1) | WO2011119772A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8653006B2 (en) | 2010-09-03 | 2014-02-18 | Purdue Research Foundation | Metabolite biomarkers for the detection of esophageal cancer using NMR |
| US20140162903A1 (en) * | 2012-10-31 | 2014-06-12 | Purdue Research Foundation | Metabolite Biomarkers For Forecasting The Outcome of Preoperative Chemotherapy For Breast Cancer Treatment |
| CN105451657A (zh) | 2013-03-15 | 2016-03-30 | 霍罗吉克公司 | 用于导航断层合成堆叠的包括自动聚焦的系统和方法 |
| EP3064940B1 (en) * | 2013-10-28 | 2019-07-03 | Salivatech Co., Ltd. | Salivary biomarker for pancreatic cancer |
| WO2015109263A2 (en) | 2014-01-17 | 2015-07-23 | University Of Washington | Biomarkers for detecting and monitoring colon cancer |
| BR112017004773B1 (pt) * | 2014-09-10 | 2024-02-27 | Fundação Pio Xii Hospital De Câncer De Barretos Cnpj/Mf | Biomarcadores para avaliação do câncer de mama |
| EP3262416B1 (en) * | 2015-02-27 | 2018-12-26 | Hosmotic SRL | Method for the diagnosis of endometrial carcinoma |
| JP6051257B2 (ja) * | 2015-04-15 | 2016-12-27 | ライオン株式会社 | 脂質異常症への罹患しやすさを試験する方法 |
| CN104991010B (zh) * | 2015-07-29 | 2017-10-13 | 中国药科大学 | 一种区分乳腺癌亚型生物标志物的组合物 |
| WO2017213246A1 (ja) * | 2016-06-10 | 2017-12-14 | 株式会社日立製作所 | 尿中代謝物による疾病診断法 |
| MX2019002918A (es) | 2016-09-16 | 2019-07-18 | Dyax Corp | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
| WO2018183548A1 (en) | 2017-03-30 | 2018-10-04 | Hologic, Inc. | System and method for hierarchical multi-level feature image synthesis and representation |
| US11403483B2 (en) * | 2017-06-20 | 2022-08-02 | Hologic, Inc. | Dynamic self-learning medical image method and system |
| TWI716093B (zh) * | 2019-09-02 | 2021-01-11 | 高雄醫學大學 | 以代謝物標誌為基礎之預測乳癌復發風險的方法 |
| KR102283623B1 (ko) * | 2019-11-06 | 2021-07-30 | (의료)길의료재단 | 초음파 기법을 활용한 gc-ms 동시 분석 방법 |
| CN112630363A (zh) * | 2020-12-31 | 2021-04-09 | 四川大学华西医院 | 一种MXene生物响应特性代谢组学分析方法 |
| WO2025118084A1 (en) * | 2023-12-08 | 2025-06-12 | Biomark Cancer Systems Inc. | Early breast cancer detection using blood-based metabolomic profiling |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0727664A3 (en) * | 1995-02-15 | 1996-11-20 | Bayer Ag | Tumor markers to detect the recurrence of breast cancer |
| US20070221835A1 (en) * | 2006-03-06 | 2007-09-27 | Daniel Raftery | Combined Spectroscopic Method for Rapid Differentiation of Biological Samples |
| US20090075284A1 (en) * | 2006-09-19 | 2009-03-19 | The Regents Of The University Of Michigan | Metabolomic profiling of prostate cancer |
| BRPI0815095B1 (pt) * | 2007-07-17 | 2021-04-13 | Metabolon, Inc | Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo |
| US8980637B2 (en) * | 2007-10-04 | 2015-03-17 | Purdue Research Foundation | Breast cancer biomarkers and identification methods using NMR and gas chromatography-mass spectrometry |
| CA2778226A1 (en) * | 2009-10-09 | 2011-04-14 | Carolyn Slupsky | Methods for diagnosis, treatment and monitoring of patient health using metabolomics |
| EP2488666A4 (en) * | 2009-10-13 | 2013-05-29 | Purdue Research Foundation | BIOMARKERS AND IDENTIFICATION METHOD FOR THE EARLY DETECTION AND PREDICTION OF THE REPRESENTATION OF BREAST CANCER BY NMR |
-
2011
- 2011-03-23 JP JP2013501439A patent/JP2013522652A/ja active Pending
- 2011-03-23 EP EP20110760174 patent/EP2550533A4/en not_active Withdrawn
- 2011-03-23 CA CA2793735A patent/CA2793735A1/en not_active Abandoned
- 2011-03-23 WO PCT/US2011/029681 patent/WO2011119772A1/en not_active Ceased
- 2011-03-23 AU AU2011232434A patent/AU2011232434B2/en not_active Ceased
- 2011-03-23 MX MX2012010852A patent/MX2012010852A/es unknown
-
2012
- 2012-09-21 US US13/624,042 patent/US20130023056A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522652A5 (enExample) | ||
| Zygulska et al. | Novel diagnostic biomarkers in colorectal cancer | |
| Tellez-Gabriel et al. | Current status of circulating tumor cells, circulating tumor DNA, and exosomes in breast cancer liquid biopsies | |
| Radaic et al. | Biological biomarkers of oral cancer | |
| Pan et al. | Biomarkers in hepatocellular carcinoma: current status and future perspectives | |
| Piao et al. | Role of exosomal miRNA in bladder cancer: a promising liquid biopsy biomarker | |
| JP2010537170A5 (enExample) | ||
| Li et al. | Current status of ctDNA in precision oncology for hepatocellular carcinoma | |
| EP3206034A3 (en) | Use of fatty acids in methods for detecting cancer | |
| WO2012112970A3 (en) | Methods and compositions for detecting genetic material | |
| Caviglia et al. | Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II | |
| JP2013544098A5 (enExample) | ||
| Monedeiro et al. | A review of GC-based analysis of non-invasive biomarkers of colorectal cancer and related pathways | |
| Santos et al. | Microrna biomarkers as promising tools for early colorectal cancer screening—a comprehensive review | |
| AU2018203197A1 (en) | Methods of detecting autoimmune or immune-related diseases or conditions | |
| Clarke et al. | Markers for detection of prostate cancer | |
| Buchard et al. | Two metabolomics phenotypes of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis severity | |
| Yu et al. | Promising novel biomarkers for hepatocellular carcinoma: diagnostic and prognostic insights | |
| Lui et al. | Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screening | |
| Kadam et al. | Metabolomics of gastric cancer | |
| Tumas et al. | Towards a personalized approach in pancreatic cancer diagnostics through plasma amino acid analysis | |
| WO2012139052A3 (en) | Antibody biomarkers for diabetes | |
| Cespiati et al. | An overview of hepatocellular carcinoma surveillance focusing on non-cirrhotic NAFLD patients: A challenge for physicians | |
| Razghonova et al. | Endometrial Cancer Is Associated with Altered Metabolism and Composition of Fatty Acids | |
| Costanzi et al. | The role of extracellular vesicles as shuttles of RNA and their clinical significance as biomarkers in hepatocellular carcinoma |